FR13C0035I1 - - Google Patents

Info

Publication number
FR13C0035I1
FR13C0035I1 FR13C0035C FR13C0035I1 FR 13C0035 I1 FR13C0035 I1 FR 13C0035I1 FR 13C0035 C FR13C0035 C FR 13C0035C FR 13C0035 I1 FR13C0035 I1 FR 13C0035I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0035I1 publication Critical patent/FR13C0035I1/fr
Application granted granted Critical
Publication of FR13C0035I2 publication Critical patent/FR13C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0035C 2003-08-05 2013-07-04 Nouveaux derives d'insuline Active FR13C0035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
FR13C0035I1 true FR13C0035I1 (enrdf_load_stackoverflow) 2013-08-09
FR13C0035I2 FR13C0035I2 (fr) 2014-03-07

Family

ID=34117520

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0035C Active FR13C0035I2 (fr) 2003-08-05 2013-07-04 Nouveaux derives d'insuline
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Country Status (18)

Country Link
US (3) US7615532B2 (enrdf_load_stackoverflow)
EP (3) EP2107069B1 (enrdf_load_stackoverflow)
JP (1) JP4463814B2 (enrdf_load_stackoverflow)
KR (1) KR101159559B1 (enrdf_load_stackoverflow)
AU (2) AU2004261353B2 (enrdf_load_stackoverflow)
BE (2) BE2013C035I2 (enrdf_load_stackoverflow)
BR (1) BRPI0413276B8 (enrdf_load_stackoverflow)
CA (1) CA2531988C (enrdf_load_stackoverflow)
CY (5) CY1113850T1 (enrdf_load_stackoverflow)
FR (2) FR13C0035I2 (enrdf_load_stackoverflow)
HU (1) HUS1300033I1 (enrdf_load_stackoverflow)
IL (1) IL172980A (enrdf_load_stackoverflow)
LU (2) LU92213I2 (enrdf_load_stackoverflow)
MX (1) MXPA06001283A (enrdf_load_stackoverflow)
NO (5) NO340925B1 (enrdf_load_stackoverflow)
PL (1) PL2107069T3 (enrdf_load_stackoverflow)
RU (1) RU2518460C2 (enrdf_load_stackoverflow)
WO (1) WO2005012347A2 (enrdf_load_stackoverflow)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648933B1 (en) * 2003-07-25 2009-06-17 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
ES2438145T3 (es) * 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
BRPI0712041A2 (pt) * 2006-05-09 2011-12-27 Novo Nordisk As derivado de insulina
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
US20090306337A1 (en) 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
KR101699370B1 (ko) 2006-09-22 2017-02-14 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
US20100144592A1 (en) * 2007-06-01 2010-06-10 Nove Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
MX2010001645A (es) 2007-08-15 2010-03-10 Novo Nordisk As Analogos de insulina con una porcion de acil y alquilenglicol.
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
JP5715418B2 (ja) * 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
EP2597103B1 (en) 2007-11-16 2016-11-02 Novo Nordisk A/S Stable pharmaceutical compositions comprising liraglutide and degludec
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
CA2738615A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
MX2011007544A (es) 2009-01-23 2011-08-12 Novo Nordisk As Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
WO2011051312A1 (en) 2009-10-30 2011-05-05 Novo Nordisk A/S Derivatives of cgrp
JP5908847B2 (ja) * 2010-01-12 2016-04-26 ノヴォ ノルディスク アー／エス インスリンペプチドを経口投与するための医薬組成物
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
ES2541369T3 (es) 2010-02-16 2015-07-17 Novo Nordisk A/S Factor VIII recombinante modificado
BR112012028766A2 (pt) 2010-05-10 2017-06-13 Novo Nordisk As processo para a preparação de complexos de insulina e zinco
WO2011146973A1 (en) 2010-05-25 2011-12-01 Monash University Insulin analogues
KR20130036290A (ko) * 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
JP6013330B2 (ja) 2010-06-23 2016-10-25 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するヒトインスリン
US20140315797A1 (en) 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
US20130261051A1 (en) * 2010-10-27 2013-10-03 Thue Johansen Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
US20140011728A1 (en) 2011-02-15 2014-01-09 Novo Nordisk A/S Long-acting il-1 receptor antagonists
US20140031278A1 (en) * 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
CN103458873B (zh) 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
CA2858253A1 (en) * 2011-12-15 2013-06-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Human insulin analogue and acylated derivative thereof
WO2013093009A1 (en) 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
EP2844274B1 (en) 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2908846A1 (en) 2012-10-17 2015-08-26 Novo Nordisk A/S Fatty acid acylated d-amino acids for oral peptide delivery
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
US20160296602A1 (en) * 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015124612A1 (en) 2014-02-18 2015-08-27 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN108026156A (zh) 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
EP3495384A4 (en) * 2016-08-02 2020-02-26 Jiangsu Hengrui Medicine Co., Ltd. ACYLATED DERIVATIVE OF HUMAN INSULIN OR THE LIKE
CN110022935A (zh) 2016-11-28 2019-07-16 诺和诺德股份有限公司 用于心血管病况的德谷胰岛素
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US11673933B2 (en) 2016-11-28 2023-06-13 Novo Nordisk A/S Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
BR112020015238A2 (pt) 2018-02-09 2020-12-29 Jiangsu Hengrui Medicine Co., Ltd. Gene precursor otimizado por códon e gene de peptídeo sinal de análogo de insulina humana
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
CN112313755B (zh) 2018-06-26 2024-05-28 诺和诺德股份有限公司 为基础胰岛素滴定提供剂量推荐的系统
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20240025957A1 (en) 2019-12-30 2024-01-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin Derivative
WO2021231676A1 (en) 2020-05-15 2021-11-18 Eli Lilly And Company Extended time action acylated insulin compounds
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4471053A1 (en) 2022-01-28 2024-12-04 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK45590D0 (enrdf_load_stackoverflow) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
UA41502C2 (uk) 1991-12-20 2001-09-17 Ново Нордіск А/С Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
CN1056618C (zh) 1993-09-17 2000-09-20 诺沃挪第克公司 酰化的胰岛素和含有这种胰岛素的药物组合物
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
ES2230607T3 (es) * 1996-07-11 2005-05-01 Novo Nordisk A/S Metodo selectivo de acilacion.
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2218622T3 (es) 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
EP0971729B1 (en) 1997-03-20 2002-07-03 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
JP2001518915A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
EP1005490B1 (en) * 1997-03-20 2006-03-29 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP1283051B1 (en) 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
TR200001050T2 (tr) 1997-10-24 2000-08-21 Eli Lilly And Company Çözünmez insülin bileşimleri
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
BR9813128A (pt) * 1997-10-24 2000-08-15 Novo Nordisk As Agregado solúvel em água de derivados de insulina, derivado de insulina, preparação farmacêutica, e, processo para tratamento de diabetes mellitus
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ATE218364T1 (de) 1998-10-16 2002-06-15 Novo Nordisk As Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
CZ307715B6 (cs) 1999-02-22 2019-03-06 University Of Connecticut Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
US8003605B2 (en) 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
EP1506230B1 (en) 2002-05-07 2011-01-19 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
CN1708314A (zh) 2002-10-29 2005-12-14 阿尔萨公司 稳定化的固态多肽微粒
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
BRPI0407303A (pt) 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
PT1597367E (pt) 2003-02-19 2010-09-02 Scripps Research Inst Antigénio glicoproteína sima 135 expresso em células tumorais humanas metastáticas
EA200501422A1 (ru) 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
SI2107069T1 (sl) 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
EP1706150B1 (en) 2003-12-23 2012-04-25 Pharmacia Corporation Stable growth hormone liquid formulation
DK1740154T3 (da) 2004-03-12 2009-08-31 Biodel Inc Insulinsammensætninger med forbedret absorption
AU2005249232B2 (en) 2004-06-01 2010-08-05 Ares Trading S.A. Method of stabilizing proteins
ES2349472T3 (es) 2004-08-12 2011-01-03 Schering Corporation Formulación estable de interferón pegilado.
EP1778723B1 (en) 2004-08-17 2012-11-14 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
EP1817049B1 (en) 2004-11-22 2012-08-01 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
CA2593112A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
ES2438145T3 (es) * 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2007096431A1 (en) 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
BRPI0712041A2 (pt) 2006-05-09 2011-12-27 Novo Nordisk As derivado de insulina
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2597103B1 (en) 2007-11-16 2016-11-02 Novo Nordisk A/S Stable pharmaceutical compositions comprising liraglutide and degludec
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
NO2024003I1 (no) 2024-01-16
US8828923B2 (en) 2014-09-09
US7615532B2 (en) 2009-11-10
AU2004261353A1 (en) 2005-02-10
FR13C0035I2 (fr) 2014-03-07
KR20060132543A (ko) 2006-12-21
BRPI0413276A (pt) 2006-10-10
LU92213I9 (enrdf_load_stackoverflow) 2018-11-19
LU92226I2 (fr) 2015-04-29
CY2013027I2 (el) 2024-09-20
EP2107069A2 (en) 2009-10-07
BE2013C035I2 (enrdf_load_stackoverflow) 2023-12-14
KR101159559B1 (ko) 2012-06-26
CY2013027PI1 (el) 2015-11-04
EP2107069B1 (en) 2013-01-16
US20060183668A1 (en) 2006-08-17
NO2018002I1 (no) 2018-01-11
CA2531988A1 (en) 2005-02-10
NO2018003I1 (no) 2018-01-11
IL172980A (en) 2013-10-31
NO2024004I1 (no) 2024-01-16
HUS1300033I1 (hu) 2016-08-29
CY2013027I1 (el) 2024-09-20
CY2013029I1 (enrdf_load_stackoverflow) 2024-09-20
CY2013029PI1 (el) 2015-11-04
RU2518460C2 (ru) 2014-06-10
NO340925B1 (no) 2017-07-17
RU2008152033A (ru) 2010-07-10
EP2107069A3 (en) 2009-11-25
AU2010200497A1 (en) 2010-03-04
CY1113850T1 (el) 2015-11-04
IL172980A0 (en) 2006-06-11
NO2018002I2 (no) 2018-08-20
AU2004261353B2 (en) 2009-12-10
CY2013027PI2 (el) 2015-11-04
EP2264065B1 (en) 2017-03-08
WO2005012347A2 (en) 2005-02-10
LU92213I2 (fr) 2013-08-23
BE2013C038I2 (enrdf_load_stackoverflow) 2023-12-14
US20100009899A1 (en) 2010-01-14
MXPA06001283A (es) 2006-04-11
US20140349925A1 (en) 2014-11-27
LU92226I9 (enrdf_load_stackoverflow) 2018-11-19
EP2264065A2 (en) 2010-12-22
PL2107069T3 (pl) 2013-06-28
JP4463814B2 (ja) 2010-05-19
BRPI0413276B8 (pt) 2021-05-25
EP1660531A2 (en) 2006-05-31
BRPI0413276B1 (pt) 2020-03-03
WO2005012347A3 (en) 2005-04-14
CA2531988C (en) 2016-06-28
NO20061026L (no) 2006-03-02
JP2007523881A (ja) 2007-08-23
CY2013029I2 (el) 2024-09-20
EP2264065A3 (en) 2011-07-27
CY2013029PI2 (el) 2015-11-04
AU2010200497B2 (en) 2014-10-23
FR13C0038I1 (fr) 2013-08-09

Similar Documents

Publication Publication Date Title
CY2013029I1 (enrdf_load_stackoverflow)
BE2013C075I2 (enrdf_load_stackoverflow)
BE2013C069I2 (enrdf_load_stackoverflow)
BE2013C067I2 (enrdf_load_stackoverflow)
BE2013C034I2 (enrdf_load_stackoverflow)
JP2004080992A5 (enrdf_load_stackoverflow)
JP2004134051A5 (enrdf_load_stackoverflow)
JP2004044803A5 (enrdf_load_stackoverflow)
JP2003329713A5 (enrdf_load_stackoverflow)
JP2004101514A5 (enrdf_load_stackoverflow)
BE2012C053I2 (enrdf_load_stackoverflow)
JP2004003075A5 (enrdf_load_stackoverflow)
IN2006CH02600A (enrdf_load_stackoverflow)
JP2004136363A5 (enrdf_load_stackoverflow)
JP2004007401A5 (enrdf_load_stackoverflow)
JP2004124696A5 (enrdf_load_stackoverflow)
JP2004154772A5 (enrdf_load_stackoverflow)
DE50310392D1 (enrdf_load_stackoverflow)
JP2004092902A5 (enrdf_load_stackoverflow)
JP2004118176A5 (enrdf_load_stackoverflow)
JP2003219554A5 (enrdf_load_stackoverflow)
JP2004177925A5 (enrdf_load_stackoverflow)
AU2002327042A1 (enrdf_load_stackoverflow)
AU2002321535A1 (enrdf_load_stackoverflow)
AU2002322913A1 (enrdf_load_stackoverflow)